TRDX – What’s up Doc?

Posted by Admin on July 12, 2010 under Penny Stock Alerts Blog | Be the First to Comment

Good morning pllayyyyaaaazz!! I sent out the alert on TRDX early so everyone would have time to do their research and be ready to go. The penny stock picks have been hot! Hot penny stocks are flowing out of me, like the Force flows out of Luke.

You probably came across the news that came out after the close on Friday. TRDX announced plans to appoint Dr. Bahige Baroudy of Genesis Biopharma to the equivalent role of Chief Science Officer at TRDX for the continued development of a potential cure for diabetic neuropathy.

Dr. Bahige Baroudy is more than just a guy with a funny name. Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and he even earned a place on “The Scientific American 50″ list as the top Research Leader in 2003 in this category.

He seems like the perfect fit.

Having someone like him at the helm of this project is, in my opinion, a very good step in making the cure for diabetic neuropathy a reality.

Of course, the bottom line is if investors see this news as strong, which they quite possibly will…TRDX could be in for some nice gains.

Market is opening soon. See you out there…

PSA – Penny Psycho

www.pennystockalerts.com

Don’t invest based on what I say, do your own research and consult with a licensed professional before investing, and only invest what you are prepared to lose.

Disclaimer – By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment advice or anything of an advisory nature. Always do your own research and consult with an licensed investment professional before investing. Companies with low share prices are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. We have been compensated up to twenty five thousand dollars to conduct investor relations marketing for Scimedent Health Corp by a third party Creme Delletex, Inc/Shawn Zeremski, . This compensation constitutes a conflict of interest in our ability to be unbiased. Therefore this newsletter should be read as a commercial advertisement only. The third party or their affiliates may wish to liquidate shares, which has the potential to hurt share prices. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at pennystockalerts.com/disclaimer.